Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore Sells 74,000 Shares
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO John Maraganore sold 74,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $126.86, for a total value of $9,387,640.00. Following the completion of the transaction, the chief executive officer now directly owns 223,710 shares in the company, valued at $28,379,850.60. The sale was disclosed in a filing with the SEC, which is available through this link.
Shares of Alnylam Pharmaceuticals, Inc. (ALNY) traded up $1.13 on Friday, hitting $127.51. The stock had a trading volume of 901,011 shares, compared to its average volume of 1,135,227. Alnylam Pharmaceuticals, Inc. has a 52 week low of $35.98 and a 52 week high of $147.63. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The company had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. During the same quarter last year, the business earned ($1.21) earnings per share. Alnylam Pharmaceuticals’s revenue was up 24.8% compared to the same quarter last year. research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -5.33 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/11/17/alnylam-pharmaceuticals-inc-alny-ceo-john-maraganore-sells-74000-shares.html.
Several institutional investors and hedge funds have recently modified their holdings of ALNY. Pacer Advisors Inc. grew its stake in Alnylam Pharmaceuticals by 22.0% during the second quarter. Pacer Advisors Inc. now owns 11,610 shares of the biopharmaceutical company’s stock worth $926,000 after purchasing an additional 2,093 shares during the period. California Public Employees Retirement System grew its stake in Alnylam Pharmaceuticals by 14.4% during the second quarter. California Public Employees Retirement System now owns 126,700 shares of the biopharmaceutical company’s stock worth $10,106,000 after purchasing an additional 15,900 shares during the period. Verition Fund Management LLC acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth approximately $1,060,000. Hemenway Trust Co LLC acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth approximately $235,000. Finally, Federated Investors Inc. PA grew its stake in Alnylam Pharmaceuticals by 522.9% during the second quarter. Federated Investors Inc. PA now owns 62,293 shares of the biopharmaceutical company’s stock worth $4,968,000 after purchasing an additional 52,293 shares during the period. Institutional investors own 92.73% of the company’s stock.
A number of research analysts have commented on the company. BidaskClub raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. JMP Securities upped their price objective on Alnylam Pharmaceuticals from $101.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, September 20th. Barclays PLC upped their price objective on Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the company an “overweight” rating in a report on Wednesday, November 8th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $110.00 price objective (down from $126.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Finally, FBR & Co assumed coverage on Alnylam Pharmaceuticals in a report on Monday, October 30th. They issued a “buy” rating and a $150.00 price objective on the stock. Three analysts have rated the stock with a sell rating, six have given a hold rating and seventeen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $121.85.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.